Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Association of Murine Double Minute 2 Genotypes and Lung Cancer Risk

YU-CHAO LIN, WEN-SHIN CHANG, TE-CHUN SHEN, HSIN-TING LI, CHIA-HSIANG LI, YU-CHEN HSIAU, YUN-CHI WANG, CHENG-NAN WU, CHI-LI GONG, ZHI-HONG WANG, CHIA-WEN TSAI, TE-CHUN HSIA and DA-TIAN BAU
In Vivo May 2020, 34 (3) 1047-1052; DOI: https://doi.org/10.21873/invivo.11874
YU-CHAO LIN
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WEN-SHIN CHANG
2Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TE-CHUN SHEN
2Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HSIN-TING LI
2Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
3Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIA-HSIANG LI
2Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU-CHEN HSIAU
2Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUN-CHI WANG
2Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHENG-NAN WU
4Department of Medical Laboratory Science and Biotechnology, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHI-LI GONG
2Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZHI-HONG WANG
5Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIA-WEN TSAI
2Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
4Department of Medical Laboratory Science and Biotechnology, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
TE-CHUN HSIA
2Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
DA-TIAN BAU
1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
2Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
6Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: The aim of this study was to evaluate the contribution of human mouse double minute 2 (MDM2) gene polymorphisms to the risk of Taiwan lung cancer. Materials and Methods: In this case-control study, the association of MDM2 rs2279744 genotypes with lung cancer risk was investigated among 358 lung cancer patients and 716 age-, gender- and smoking status-matched controls in Taiwan. Results: The percentages of MDM2 rs2279744 GT and GG genotypes were 50.0% and 27.4% in lung cancer group and 50.0% and 26.5% in control group, respectively [odds ratio (OR)=1.03 and 1.07, 95% confidence interval (CI)=0.75-1.43 and 0.75-1.53, respectively]. The analysis about allelic frequency showed that G allele at MDM2 rs2279744 conferred a non-significant increased cancer risk (OR=1.03, 95%CI=0.86-1.24). Conclusion: Polymorphisms of MDM2 rs2279744 may play a role in lung carcinogenesis. However, the studied genotypes were not shown as predictors of lung cancer susceptibility.

  • Mouse double minute 2
  • MDM2
  • polymorphisms
  • genotypes
  • lung cancer
  • Taiwan

According to GLOBOCAN 2018 statistics about cancer occurrence and mortality reported by the International Agency for Research on Cancer, lung cancer is the first cause of cancer death, accounting for about 2.1 million newly-diagnosed cases and 1.8 million deaths worldwide (1). Thus, it is urgently important for translational scientists to figure out effective methodologies predicting and preventing the risk of lung cancer, improving prognosis and extending the survival periods for the lung cancer patients.

The initiation and development of lung cancer is related to complicated factors including environmental, lifestyle, and genomic discrepancies, among which cigarette smoking behavior is the most risk one (2). Nevertheless, 10% to 25% of the lung cancer patients are non-smokers worldwide, and this fact indicates that the personal genomic factors also play as determiners of carcinogenesis for personal lung cancer etiology (3). In Taiwan, the incidence and mortality of lung cancer has occupied the third and first places among the common cancers for decades (4). In Taiwan, although several clinically useful genomic biomarkers for the prediction, diagnosis, and prognosis of lung cancer risk have been proposed during the recent years (5-10), the investigations about clinically practical genomic markers and the intracellular mechanisms are still in urgent need.

Mouse double minute 2 homolog (MDM2; also known as E3 ubiquitin-protein ligase), encoded by the MDM2 gene in human genome, acts as an E3 ubiquitin ligase, recognizing the N-terminal trans-activation domain at p53, and also suppresses the activation of p53 transcription. The most common single nucleotide polymorphism (SNP) of MDM2 gene is known as “rs2279744, “SNP309”, and “SNP309T>G”; it has been examined for its role in cancer etiology and treatment responses. MDM2 rs2279744 has been identified as a T to G substitution at the nucleotide 309 in the first intron, regulating the binding affinity between MDM2 and transcription factor Sp1 (11). In literature, MDM2 rs2279744 has been reported to be closely related to accelerated tumor formation in both hereditary and sporadic cancers and to serve as a rat-limiting factor during tumorigenesis (11). Thus, it is hypothesized that the genomic variant may critically determine the expression level of MDM2 and influence individual's susceptibility to several types of cancer. In literature, several studies have examined the contribution of MDM2 rs2279744 genotypes to various tumors, while the results are not so conclusive among the different ethnicities investigated and various types of cancer (12-14). Some studies have proposed a direct association between MDM2 rs2279744 and cancer risk (15-20); however, other reports have not confirmed this finding (21-24).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Summary of selected demographics of the 358 patients with lung cancer and the 716 matched controls.

In 2008, Liu and his colleagues have reported that there is no significant association between MDM2 rs2279744 genotypes and lung cancer risk among Caucasians (25). The group of Hancox reported that the G allele at MDM2 rs2279744 was associated with not only higher MDM2 expression levels, but also with a reduced p53 response, and hence more DNA damage and the corresponding tissue destruction. Interestingly, the G allele was associated with accelerated smoking-related decline in lung function (26). According to the literature mentioned above, MDM2 genotype and its expression may contribute to the etiology of lung cancer risk. Therefore, the aim of the current study was to reveal the genotypes of MDM2 rs2279744 among Taiwanese and evaluate their association with lung cancer risk, in Taiwan.

Materials and Methods

Selection of lung cancer patients and controls. Three hundred and fifty-eight patients with lung cancer were histologically confirmed and recruited at the medical center in central Taiwan with the approval of the Institutional Review Board of China Medical University Hospital (DMR100-IRB-284), as previously described (5, 6, 10). Briefly, the exclusion criteria of the cases were: history of any other malignancy and pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), pneumothorax, and asthma. During the same period, 760 healthy volunteers were selected from the databank of Health Examination Cohort of China Medical University Hospital with more than 15,000 individuals as controls, matched for their age (differences less than 5 years), gender, and smoking behavior. The exclusion criteria of the control group included previous malignancy, metastasized cancer from other known or unknown origin, and any genetic or familial diseases. The controls and cases were all Taiwanese; their selected recorded characteristics are summarized in Table I.

Genotyping conditions for MDM2 rs2279744. Extraction of genomic DNA from peripheral blood leukocytes was conducted within 24 h with the QIAamp Blood Mini kit (Blossom, Taipei, Taiwan) as usual (27, 28). Then the DNA was quantified, stored long-term at −80°C, diluted and aliquoted for genotyping as a working stock at −20°C as is routinely conducted (29, 30). The MDM2 genotyping working flow including the designing of the forward and reverse primer sequences, the selection of corresponding restriction endonucleases, and the polymerase chain reaction (PCR) cycling condition set-up were previously described (31). Briefly, the cycling conditions of PCR procedure were set as: one cycle at 94°C for 5 min; followed by 35 cycles of 94°C for 30 s, 59°C for 30 s and 72°C for 30 s; last, an extension at 72°C for 10 min. The PCR products were harvested immediately after the final extension, and subjected to DNA electrophoresis. The sequences for the forward and reverse primers were 5’-GTTTTGTTGGACTGGGGCTA-3’ and 5’-CTGCGATCATCCGGACCT-3’, respectively. After the first check of successful PCR amplification procedures, all the PCR products were enzymatically digested by MspA II restriction endonuclease (New England Biolabs, Beverly, MA, USA) and then separated and identified of their MDM2 genotypes using 3% agarose gel electrophoresis. All the genotypic processing was repeated by at least two expert scientists in our team independently and blindly, as expected, the results were 100% concordant to each other.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Distributions of MDM2 rs2279744 genotypic frequencies among lung cancer patients and healthy controls.

Statistical analysis methods. The typical unpaired Student's t-test was applied to compare the distributions of continuous variables such as ages between the lung cancer patients and the control groups. The Pearson's Chi-square was applied in comparison of the distributions of the MDM2 genotypes among the investigated subgroups in comparison. The associations between MDM2 polymorphic genotypes and lung cancer risk were estimated by calculating the odds ratios (ORs) and the responding 95% confidence intervals (CIs) within logistic regression analysis. Statistically, any comparison with p-value less than 0.05 was identified as significantly different to each other.

Results

The distributions of age, sex and smoking status for the 358 lung cancer patients and 716 non-cancer healthy controls, are summarized and compared in Table I. In addition, the histology of the lung cancer patients are also collected at the bottom of Table I. Since we have applied the matching strategies focusing on age, gender and smoking status to recruit those 716 non-cancer healthy subjects as controls, the comparison results showed that there was no difference in respect to the distributions of age, gender and smoking behavior between the case and control groups (p-values all >0.05) (Table I). Among the lung cancer patients, 60.9% (218/358) were adenocarcinoma type, 29.6% (106/358) were squamous cell carcinoma type, and 9.5% (34/358) were other types.

The distributions of the MDM2 rs2279744 genotypes among the 358 lung cancer patients and 716 non-cancer healthy controls are presented in Table II. Overall, the genotypes of MDM2 rs2279744 were non-differentially distributed between the case and control groups (p for trend=0.9348) (Table II). In detail, neither the MDM2 rs2279744 GG nor the GT was associated with altered lung cancer risk, compared to the wild-type TT genotype (crude OR=1.03 and 1.07, 95%CI=0.75-1.43 and 0.75-1.53, p=0.8238 and 0.7135, respectively). After adjusting the confounding factors, the trends were still the same (adjusted OR=1.06 and 1.14, 95%CI=0.78-1.39 and 0.81-1.66, respectively). In the dominant model, there was still a non-significant association between the GT+GG genotype of MDM2 rs2279744 and lung cancer risk, compared to the TT wild-type genotype before and after adjusting those confounding factors.

So as to confirm the findings deduced from Table II, we have further conducted the analysis of allelic frequency distributions for the MDM2 rs2279744 and the results are shown in Table III. In consistence with the idea that MDM2 rs2279744 genotype was not associated with lung cancer risk, the percentage of allele G was 52.4% among the lung cancer patients, non-significantly higher than that of 51.5% among the non-cancer controls (crude and adjusted ORs=1.03 and 1.06, respectively) (Table III).

Discussion

The role of MDM2 in carcinogenesis can be both p53-dependent and p53-indepnedent. First, MDM2 is originally recognized as an oncoprotein which can directly bind to tumor suppressor p53 and down-regulate its tumor suppressive capacity. After binding with p53, MDM2 enhances the expression of p53 and the p53-mediated transactivation of MDM2, which in turn team up together to suppress the growth of soft tissue sarcomas, osteosarcomas and esophageal sarcomas (32, 33). Therefore, in the very beginning, the oncogenic properties of MDM2 were identified as p53-dependent. However, there are also some investigations showing that MDM2 is able to directly interact with other tumor suppressor proteins in p53-deficient cells (34, 35). In the same context, elevated expression of MDM2 by Ras/Raf/MEK/MAP kinase cascade has been observed in p53-deficient cells (36). All these findings indicate that the oncogenic function of MDM2 may be p53-independent.

Regarding the regulation of the MDM2 protein level, the case is more complicated. It has been found that MDM2 expression levels might be regulated at the post-transcriptional level (37, 38). The aforementioned literature all supported the idea that the complex molecular mechanisms underlying the regulation network of MDM2 gene at DNA, RNA and protein levels during tumorigenesis are largely unrevealed. Considering that MDM2 rs2279744 may closely be responsible for the regulation of MDM2 protein expression in addition to its interaction with p53, it is of great value to figure out its contribution to cancer susceptibility determination.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Allelic frequencies for MDM2 rs2279744 polymorphisms among lung cancer patients and healthy controls.

In the study, we have firstly provided solid evidence for that variant GT or TT genotype at MDM2 rs2279744 was not associated with Taiwan lung cancer risk (Table II). Also, allele T or G may not serve as a predictor for lung cancer occurrence (Table III). According to previous lung cancer genomic studies, whether MDM2 rs2279744 has a contribution to lung carcinogenesis is still controversial. In detail, some positive findings have supported that the GT and GG genotypes at MDM2 rs2279744 are associated with higher cancer risk than the wild-type TT genotype (15-20), whereas, other reports have shown no significant association with altered cancer risk (21-24). In Taiwanese population included in the present study, the MDM2 rs2279744 homo-variant GG carriers, but not GT, were found to have an increased CRC risk compared with those carrying TT genotype (31). However, MDM2 rs2279744 genotypes were not associated with lung cancer risk (Tables II and III).

Cigarette smoking is the major environmental risk factor for lung cancer, especially for non-small cell lung cancer (NSCLC) (39). Several compounds in cigarettes may induce DNA damage, thus contributing to carcinogenesis (40, 41). The tumor suppressor protein p53 plays a crucial role in the prevention of cancer initiation through cell cycle arrest, DNA repair, and apoptosis in case of DNA repair failure (42-44). MDM2 gene acts as a negative regulator of p53, and overexpression of MDM2 has been reported in many types of cancer tissues (45). In this study, we investigated the associations between the functional single nucleotide polymorphism of MDM2 rs2279744 and the risk of lung cancer in a large Taiwanese population. An overall association was not found (Tables II and III), and gene-smoking interaction analyses indicated that the variant genotypes were associated with higher risk of lung cancer neither in never smokers nor in ever smokers (data not shown). It has been reported by Liu and his colleagues that although the overall MDM2 rs2279744 genotypes are not associated with lung cancer risk among Caucasians, there is a statistically significant interaction between smoking and MDM2 genotypes. Their stratified analysis according to individual pack-years of smoking status demonstrated that the GG genotype, compared to wild-type T/T genotype, contribute to higher risk for never and mild (<30 pack-years) smokers, while to lower risk for moderate (30-57 pack-years) and heavy smokers (≥58 pack-years) (25). Further investigations are warranted to elucidate the interaction among MDM2 genotype, phenotype and smoking status.

There are several limitations of the current study. Despite the power and the representativeness of the current study, with 358 lung cancer patients and 358 controls are examined as well, a larger number of the overall population would be necessary to further examine the contributions of specific genotypes to lung cancer risk and prognosis. In addition, lung cancer patients can be further classified according to characteristics, such as gender and smoking status, or according to their cancer type, to improve the clinical applicability of the study results.

In conclusion, MDM2 rs2279744 was not associated with lung cancer risk in a representative Taiwanese population. In the near future, we are going to validate the combined effects of p53 and MDM2 on Taiwan lung cancer risk. Validation of our findings in larger population-based studies and in different ethnicities are needed.

Acknowledgements

The Authors appreciate the team of Hsia, Y.-C. Lin, T.-C. Shen and others in collection of all the participants. The perfect technology and efforts from Yu-Ting Chin, Tai-Lin Huang, Yu-Hsin Lin and Yi-Ru Huang are appreciated. This study is supported by the grant from China Medical University Hospital and Asia University (CMU108-ASIA-02).

Footnotes

  • Authors' Contributions

    Research design: Lin YC and Chang WS; patient and questionnaire summaries: Lin YC, Shen TC, Li CH and Hsia TC; experimental work: Wang YC, Li HT and Hsiau YC; statistical analysis: Wang ZH, Wu CN and Gong CL; article writing: Tsai CW and Bau DT; review and revision: Chang WS, Tsai CW and Bau DT.

  • This article is freely accessible online.

  • Conflicts of Interest

    All the Authors have declared no conflicts of interest regarding this study.

  • Received January 13, 2020.
  • Revision received January 29, 2020.
  • Accepted February 3, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Bray F,
    2. Ferlay J,
    3. Soerjomataram I,
    4. Siegel RL,
    5. Torre LA,
    6. Jemal A
    : Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018. PMID: 30207593. DOI: 10.3322/caac.21492
    OpenUrlCrossRefPubMed
  2. ↵
    1. Malhotra J,
    2. Malvezzi M,
    3. Negri E,
    4. La Vecchia C,
    5. Boffetta P
    : Risk factors for lung cancer worldwide. Eur Respir J 48: 889-902, 2016. PMID: 27174888. DOI: 10.1183/13993003.00359-2016
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Rivera GA,
    2. Wakelee H
    : Lung cancer in never smokers. Adv Exp Med Biol 893: 43-57, 2016. PMID: 26667338. DOI: 10.1007/978-3-319-24223-1_3
    OpenUrl
  4. ↵
    1. Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence
    : Cancer Registration Annual Report. Available at: https://www.hpa.gov.tw/Pages/List.aspx?nodeid=269 (Accessed on January 12th, 2020)
  5. ↵
    1. Chen GL,
    2. Wang SC,
    3. Shen TC,
    4. Tsai CW,
    5. Chang WS,
    6. Li HT,
    7. Wu CN,
    8. Chao CY,
    9. Hsia TC,
    10. Bau DT
    : The association of matrix metalloproteinas-2 promoter polymorphisms with lung cancer susceptibility in Taiwan. Chin J Physiol 62: 210-216, 2019. PMID: 31670285. DOI: 10.4103/CJP.CJP_43_19
    OpenUrl
  6. ↵
    1. Chen GL,
    2. Wang SC,
    3. Huang WC,
    4. Chang WS,
    5. Tsai CW,
    6. Li HT,
    7. Shen TC,
    8. Hsia TC,
    9. Bau DT
    : The association of MMP-11 promoter polymorphisms with susceptibility to lung cancer in Taiwan. Anticancer Res 39: 5375-5380, 2019. PMID: 31570432. DOI: 10.21873/anticanres.13731
    OpenUrlAbstract/FREE Full Text
    1. Shen TC,
    2. Chang WS,
    3. Hsia TC,
    4. Li HT,
    5. Chen WC,
    6. Tsai CW,
    7. Bau DT
    : Contribution of programmed cell death 6 genetic variations, gender, and smoking status to lung cancer. Onco Targets Ther 12: 6237-6244, 2019. PMID: 31496727. DOI: 10.2147/OTT.S205544
    OpenUrl
    1. Wu MF,
    2. Wang YC,
    3. Li HT,
    4. Chen WC,
    5. Liao CH,
    6. Shih TC,
    7. Chang WS,
    8. Tsai CW,
    9. Hsia TC,
    10. Bau DT
    : The contribution of interleukin-12 genetic variations to Taiwanese lung cancer. Anticancer Res 38: 6321-6327, 2018. PMID: 30396953. DOI: 10.21873/anticanres.12989
    OpenUrlAbstract/FREE Full Text
    1. Chen GL,
    2. Shen TC,
    3. Chang WS,
    4. Tsai CW,
    5. Li HT,
    6. Chuang CL,
    7. Lai YL,
    8. Yueh TC,
    9. Hsia TC,
    10. Wang SC,
    11. Bau DT
    : The contribution of MMP-7 promoter polymorphisms to Taiwan lung cancer susceptibility. Anticancer Res 38: 5671-5677, 2018. PMID: 30275186. DOI: 10.21873/anticanres.12903
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Shen TC,
    2. Chang WS,
    3. Tsai CW,
    4. Chao CY,
    5. Lin YT,
    6. Hsiao CL,
    7. Hsu CL,
    8. Chen WC,
    9. Hsia TC,
    10. Bau DT
    : The contribution of matrix metalloproteinase-1 promoter genotypes in Taiwan lung cancer risk. Anticancer Res 38: 253-257, 2018. PMID: 29277780. DOI: 10.21873/anticanres.12215
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Bond GL,
    2. Hu W,
    3. Bond EE,
    4. Robins H,
    5. Lutzker SG,
    6. Arva NC,
    7. Bargonetti J,
    8. Bartel F,
    9. Taubert H,
    10. Wuerl P,
    11. Onel K,
    12. Yip L,
    13. Hwang SJ,
    14. Strong LC,
    15. Lozano G,
    16. Levine AJ
    : A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602, 2004. PMID: 15550242. DOI: 10.1016/j.cell.2004.11.022
    OpenUrlCrossRefPubMed
  9. ↵
    1. Lind H,
    2. Zienolddiny S,
    3. Ekstrom PO,
    4. Skaug V,
    5. Haugen A
    : Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119: 718-721, 2006. PMID: 16496380. DOI: 10.1002/ijc.21872
    OpenUrlCrossRefPubMed
    1. Hong Y,
    2. Miao X,
    3. Zhang X,
    4. Ding F,
    5. Luo A,
    6. Guo Y,
    7. Tan W,
    8. Liu Z,
    9. Lin D
    : The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65: 9582-9587, 2005. PMID: 16230424. DOI: 10.1158/0008-5472.CAN-05-1460
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Ma H,
    2. Hu Z,
    3. Zhai X,
    4. Wang S,
    5. Wang X,
    6. Qin J,
    7. Jin G,
    8. Liu J,
    9. Wang X,
    10. Wei Q,
    11. Shen H
    : Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240: 261-267, 2006. PMID: 16288830. DOI: 10.1016/j.canlet.2005.09.019
    OpenUrlCrossRefPubMed
  11. ↵
    1. Alazzouzi H,
    2. Suriano G,
    3. Guerra A,
    4. Plaja A,
    5. Espin E,
    6. Armengol M,
    7. Alhopuro P,
    8. Velho S,
    9. Shinomura Y,
    10. Gonzalez-Aguilera JJ,
    11. Yamamoto H,
    12. Aaltonen LA,
    13. Moreno V,
    14. Capella G,
    15. Peinado MA,
    16. Seruca R,
    17. Arango D,
    18. Schwartz S Jr..
    : Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. J Med Genet 44: 75-80, 2007. PMID: 16825434. DOI: 10.1136/jmg. 2006.042572
    OpenUrlAbstract/FREE Full Text
    1. Joshi AM,
    2. Budhathoki S,
    3. Ohnaka K,
    4. Mibu R,
    5. Tanaka M,
    6. Kakeji Y,
    7. Maehara Y,
    8. Okamura T,
    9. Ikejiri K,
    10. Futami K,
    11. Maekawa T,
    12. Yasunami Y
    : TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. Jpn J Clin Oncol 41: 232-238, 2011. PMID: 21051533. DOI: 10.1093/jjco/hyq200
    OpenUrlCrossRefPubMed
    1. Chaar I,
    2. Arfaoui TA,
    3. El Amine el HO,
    4. Mahmoud LB,
    5. Khiari M,
    6. Sammoud S,
    7. Lounis A,
    8. Amara S,
    9. Gharbi L,
    10. Hmida AB,
    11. Mzabi S,
    12. Bouraoui S
    : Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population. Eur J Gastroenterol Hepatol 24: 320-327, 2012. PMID: 22266832. DOI: 10.1097/MEG.0b013e32834bdf84
    OpenUrlPubMed
    1. Phang BH,
    2. Linn YC,
    3. Li H,
    4. Sabapathy K
    : MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer 44: 760-766, 2008. PMID: 18313915. DOI: 10.1016/j.ejca.2008.02.007
    OpenUrlCrossRefPubMed
    1. Walsh CS,
    2. Miller CW,
    3. Karlan BY,
    4. Koeffler HP
    : Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 104: 660-664, 2007. PMID: 17123590. DOI: 10.1016/j.ygyno.2006.10.008
    OpenUrlCrossRefPubMed
  12. ↵
    1. Paulin FE,
    2. O'Neill M,
    3. McGregor G,
    4. Cassidy A,
    5. Ashfield A,
    6. Ali CW,
    7. Munro AJ,
    8. Baker L,
    9. Purdie CA,
    10. Lane DP,
    11. Thompson AM
    : MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 8: 281, 2008. PMID: 18828900. DOI: 10.1186/1471-2407-8-281
    OpenUrlPubMed
  13. ↵
    1. Alhopuro P,
    2. Ylisaukko-Oja SK,
    3. Koskinen WJ,
    4. Bono P,
    5. Arola J,
    6. Jarvinen HJ,
    7. Mecklin JP,
    8. Atula T,
    9. Kontio R,
    10. Makitie AA,
    11. Suominen S,
    12. Leivo I,
    13. Vahteristo P,
    14. Aaltonen LM,
    15. Aaltonen LA
    : The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42: 694-698, 2005. PMID: 16141004. DOI: 10.1136/jmg.2005.031260
    OpenUrlAbstract/FREE Full Text
    1. Talseth BA,
    2. Meldrum C,
    3. Suchy J,
    4. Kurzawski G,
    5. Lubinski J,
    6. Scott RJ
    : MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer 120: 563-565, 2007. PMID: 17096342. DOI: 10.1002/ijc.22339
    OpenUrlCrossRefPubMed
    1. Wilkening S,
    2. Bermejo JL,
    3. Hemminki K
    : MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 28: 2262-2267, 2007. PMID: 17827408. DOI: 10.1093/carcin/bgm191
    OpenUrlCrossRefPubMed
  14. ↵
    1. Nan H,
    2. Qureshi AA,
    3. Hunter DJ,
    4. Han J
    : A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control 20: 171-179, 2009. PMID: 18814047. DOI: 10.1007/s10552-008-9231-9
    OpenUrlCrossRefPubMed
  15. ↵
    1. Liu G,
    2. Wheatley-Price P,
    3. Zhou W,
    4. Park S,
    5. Heist RS,
    6. Asomaning K,
    7. Wain JC,
    8. Lynch TJ,
    9. Su L,
    10. Christiani DC
    : Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int J Cancer 122: 915-918, 2008. PMID: 17957785. DOI: 10.1002/ijc.23178
    OpenUrlCrossRefPubMed
  16. ↵
    1. Hancox RJ,
    2. Poulton R,
    3. Welch D,
    4. Olova N,
    5. McLachlan CR,
    6. Greene JM,
    7. Sears MR,
    8. Caspi A,
    9. Moffitt TE,
    10. Robertson SP,
    11. Braithwaite AW
    : Accelerated decline in lung function in cigarette smokers is associated with TP53/MDM2 polymorphisms. Hum Genet 126: 559-565, 2009. PMID: 19521721. DOI: 10.1007/s00439-009-0704-z
    OpenUrlCrossRefPubMed
  17. ↵
    1. Hsu SW,
    2. Gong CL,
    3. Hsu HM,
    4. Chao CC,
    5. Wang YC,
    6. Chang WS,
    7. Tsai YT,
    8. Shih LC,
    9. Tsai CW,
    10. Bau DT
    : Contribution of matrix metalloproteinase-2 promoter genotypes to nasopharyngeal cancer susceptibility and metastasis in Taiwan. Cancer Genomics Proteomics 16: 287-292, 2019. PMID: 31243109. DOI: 10.21873/cgp.20133
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Yueh TC,
    2. Wu CN,
    3. Hung YW,
    4. Chang WS,
    5. Fu CK,
    6. Pei JS,
    7. Wu MH,
    8. Lai YL,
    9. Lee YM,
    10. Yen ST,
    11. Li HT,
    12. Tsai CW,
    13. Bau DT
    : The contribution of MMP-7 genotypes to colorectal cancer susceptibility in Taiwan. Cancer Genomics Proteomics 15: 207-212, 2018. PMID: 29695403. DOI: 10.21873/cgp.20079
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Hsu NY,
    2. Wang HC,
    3. Wang CH,
    4. Chiu CF,
    5. Tseng HC,
    6. Liang SY,
    7. Tsai CW,
    8. Lin CC,
    9. Bau DT
    : Lung cancer susceptibility and genetic polymorphisms of Exo1 gene in Taiwan. Anticancer Res 29: 725-730, 2009. PMID: 19331228.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Liu CJ,
    2. Hsia TC,
    3. Tsai RY,
    4. Sun SS,
    5. Wang CH,
    6. Lin CC,
    7. Tsai CW,
    8. Huang CY,
    9. Hsu CM,
    10. Bau DT
    : The joint effect of hOGG1 single nucleotide polymorphism and smoking habit on lung cancer in Taiwan. Anticancer Res 30: 4141-4145, 2010. PMID: 21036733.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Yueh TC,
    2. Hung YW,
    3. Shih TC,
    4. Wu CN,
    5. Wang SC,
    6. Lai YL,
    7. Hsu SW,
    8. Wu MH,
    9. Fu CK,
    10. Wang YC,
    11. Ke TW,
    12. Chang WS,
    13. Tsai CW,
    14. Bau DT
    : Contribution of murine double minute 2 genotypes to colorectal cancer risk in Taiwan. Cancer Genomics Proteomics 15: 405-411, 2018. PMID: 30194081. DOI: 10.21873/cgp.20099
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Hao XP,
    2. Gunther T,
    3. Roessner A,
    4. Price AB,
    5. Talbot IC
    : Expression of mdm2 and p53 in epithelial neoplasms of the colorectum. Mol Pathol 51: 26-29, 1998. PMID: 9624416. DOI: 10.1136/mp.51.1.26
    OpenUrlPubMed
  23. ↵
    1. Momand J,
    2. Jung D,
    3. Wilczynski S,
    4. Niland J
    : The MDM2 gene amplification database. Nucleic Acids Res 26: 3453-3459, 1998. PMID: 9671804. DOI: 10.1093/nar/26.15.3453
    OpenUrlCrossRefPubMed
  24. ↵
    1. Martin K,
    2. Trouche D,
    3. Hagemeier C,
    4. Sorensen TS,
    5. La Thangue NB,
    6. Kouzarides T
    : Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694, 1995. PMID: 7791903. DOI: 10.1038/375691a0
    OpenUrlCrossRefPubMed
  25. ↵
    1. Xiao ZX,
    2. Chen J,
    3. Levine AJ,
    4. Modjtahedi N,
    5. Xing J,
    6. Sellers WR,
    7. Livingston DM
    : Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698, 1995. PMID: 7791904. DOI: 10.1038/375694a0
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ries S,
    2. Biederer C,
    3. Woods D,
    4. Shifman O,
    5. Shirasawa S,
    6. Sasazuki T,
    7. McMahon M,
    8. Oren M,
    9. McCormick F
    : Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103: 321-330, 2000. PMID: 11057904. DOI: 10.1016/s0092-8674(00)00123-9
    OpenUrlCrossRefPubMed
  27. ↵
    1. Gudas JM,
    2. Nguyen H,
    3. Klein RC,
    4. Katayose D,
    5. Seth P,
    6. Cowan KH
    : Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res 1: 71-80, 1995. PMID: 9815889.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Maya R,
    2. Balass M,
    3. Kim ST,
    4. Shkedy D,
    5. Leal JF,
    6. Shifman O,
    7. Moas M,
    8. Buschmann T,
    9. Ronai Z,
    10. Shiloh Y,
    11. Kastan MB,
    12. Katzir E,
    13. Oren M
    : ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 15: 1067-1077, 2001. PMID: 11331603. DOI: 10.1101/gad. 886901
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Doll R,
    2. Hill AB
    : Smoking and carcinoma of the lung; preliminary report. Br Med J 2: 739-748, 1950. PMID: 14772469. DOI: 10.1136/bmj.2.4682.739
    OpenUrlFREE Full Text
  30. ↵
    1. Perlow RA,
    2. Broyde S
    : Evading the proofreading machinery of a replicative DNA polymerase: induction of a mutation by an environmental carcinogen. J Mol Biol 309: 519-536, 2001. PMID: 11371169. DOI: 10.1006/jmbi.2001.4674
    OpenUrlCrossRefPubMed
  31. ↵
    1. Valavanidis A,
    2. Vlachogianni T,
    3. Fiotakis K
    : Tobacco smoke: involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int J Environ Res Public Health 6: 445-462, 2009. PMID: 19440393. DOI: 10.3390/ijerph6020445
    OpenUrlCrossRefPubMed
  32. ↵
    1. Schwartz D,
    2. Rotter V
    : p53-Dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol 8: 325-336, 1998. PMID: 10101798. DOI: 10.1006/scbi.1998.0095
    OpenUrlCrossRefPubMed
    1. Okorokov AL
    : p53 in a crosstalk between DNA repair and cell cycle checkpoints. Cell Cycle 2: 233-235, 2003. PMID: 12734432.
    OpenUrlPubMed
  33. ↵
    1. Chen J
    : The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med 6: a026104, 2016. PMID: 26931810. DOI: 10.1101/cshperspect.a026104
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Iwakuma T,
    2. Lozano G
    : MDM2, an introduction. Mol Cancer Res 1: 993-1000, 2003. PMID: 14707282.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

In Vivo: 34 (3)
In Vivo
Vol. 34, Issue 3
May-June 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Association of Murine Double Minute 2 Genotypes and Lung Cancer Risk
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Association of Murine Double Minute 2 Genotypes and Lung Cancer Risk
YU-CHAO LIN, WEN-SHIN CHANG, TE-CHUN SHEN, HSIN-TING LI, CHIA-HSIANG LI, YU-CHEN HSIAU, YUN-CHI WANG, CHENG-NAN WU, CHI-LI GONG, ZHI-HONG WANG, CHIA-WEN TSAI, TE-CHUN HSIA, DA-TIAN BAU
In Vivo May 2020, 34 (3) 1047-1052; DOI: 10.21873/invivo.11874

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Association of Murine Double Minute 2 Genotypes and Lung Cancer Risk
YU-CHAO LIN, WEN-SHIN CHANG, TE-CHUN SHEN, HSIN-TING LI, CHIA-HSIANG LI, YU-CHEN HSIAU, YUN-CHI WANG, CHENG-NAN WU, CHI-LI GONG, ZHI-HONG WANG, CHIA-WEN TSAI, TE-CHUN HSIA, DA-TIAN BAU
In Vivo May 2020, 34 (3) 1047-1052; DOI: 10.21873/invivo.11874
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Systemic Administration of Lipopolysaccharide from Porphyromonas gingivalis Decreases Neprilysin Expression in the Mouse Hippocampus
  • Monitoring T-Cell Kinetics in the Early Recovery Period of Lung Transplantation Cases by Copy Number Levels of T-Cell Receptor Excision Circle
  • Successful Surgical Outcome of Feline Inductive Odontogenic Tumor in Three Cats
Show more Experimental Studies

Similar Articles

Keywords

  • Mouse double minute 2
  • MDM2
  • polymorphisms
  • genotypes
  • lung cancer
  • Taiwan
In Vivo

© 2023 In Vivo

Powered by HighWire